MARATTO

article · Egyptian Journal of Cancer and Biomedical Research.

Developing a magnetite/mesoporous silica core /shell system for enhancing the anti-cancer performance of Doxorubicin at low doses for breast cancer treatment

Abstract

Doxorubicin (DOX) as one of the main chemotherapies used in breast cancer in the form of many dosage forms such as encapsulation within pegylated liposomes and by injection. Both dosage forms have several side effects, most importantly dilated cardiomyopathy, erythema, acral erythema, and others. Also, DOX acquires resistance in dose-dependent manner by time. Consequently, there is an urgent need for novel approaches and strategies to improve current chemotherapeutic agents’ delivery systems including DOX. Nanoparticles (NPs) have found their way in almost all aspects of biomedical applications within the last two decades, such as medical diagnostics, imaging, and drug/gene delivery systems. Mesoporous silica NPs are of great interest as an efficient drug/gene delivery system due to their unique properties. In the same context, magnetic nanoparticles contributed significantly to biomedicine, for their apparent features emerging at the nanoscale. Core/shell nanoparticles have potential characteristics as they incorporate the multiple merits of the used nanoparticles. Herein, we have developed multifunctional iron oxide/mesoporous silica/amino; core/shell (M/silica/Amino), by sonochemical method, loaded with DOX as a Drug Delivery System (DDS) for breast cancer treatment.

Research topics

  • Mesoporous Materials and Catalysis
  • Catalytic Processes in Materials Science
  • Zeolite Catalysis and Synthesis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/jcbr.2024.236764.1315

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.